en · de · es · fr · pt
sr9009-notes.peptides6088.com › Wiki › Sr9009 Background And Receptor Mechanism — Questions and Answers

Sr9009 Background And Receptor Mechanism — Questions and Answers

By Editorial Desk · published 2026-04-23 · last reviewed 2026-05-15 · Wiki

A practical reference on circadian clock: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Related pages on this site

SR9009 Identity and Mechanism

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Background from the literature

20 September 74 of 75 persons on an Air Vietnam Douglas DC-4 were killed after a mid-air collision with a USAF F-4 Phantom. Both aircraft were approaching Da Nang Air Base when the F-4 clipped the wing of the DC-4 causing it to crash into a field, killing two farmers on the ground. The PAVN/VC attacked Tu Van refugee center in Quảng Ngãi Province, killing 8 persons and wounding two, all families of local People's Self-Defense Force members. In nearby Bình Sơn District, eight members of a police official's family were killed.

=== Ischemia and hypoxia === Blood vessels constrict in tissue that becomes cold and dilate in warm tissue, altering blood flow to the area. Thus keeping the tissues warm is probably necessary to fight both infection and ischemia. Some healthcare professionals use 'radiant bandages' to keep the area warm, and care must be taken during surgery to prevent hypothermia, which increases rates of post-surgical infection. Underlying ischemia may also be treated surgically by arterial revascularization, for example in diabetic ulcers, and patients with venous ulcers may undergo surgery to correct vein dysfunction. Diabetics that are not candidates for surgery (and others) may also have their tissue oxygenation increased by Hyperbaric Oxygen Therapy, or HBOT, which may provide a short-term improvement in healing by improving the oxygenated blood supply to the wound. In addition to killing bacteria, higher oxygen content in tissues speeds growth factor production, fibroblast growth, and angiogenesis. However, increased oxygen levels also means increased production of ROS. Antioxidants, molecules that can lose an electron to free radicals without themselves becoming radicals, can lower levels of oxidants in the body and have been used with some success in wound healing. Low level laser therapy has been repeatedly shown to significantly reduce the size and severity of diabetic ulcers as well as other pressure ulcers. Pressure wounds are often the result of local ischemia from the increased pressure.

== Clinical significance == A tumor of the delta cells is called a "somatostatinoma". When a person is infected with H. pylori the lower region of the stomach, the antrum, is predominantly inflamed. This is where most of the δ-cells in the stomach are. The bacteria produce a cloud of ammonia around themselves using urease to protect them from the stomach acid; however, this reacts with the acid producing ammonium which is toxic to cells. This leads to many of the δ-cells dying, an effect that is further compounded by the low PD-L1 expression on the δ-cells as compared to gastric G cells (resulting in higher susceptibility of δ-cells to inflammatory responses). In turn, this results in a lower level of somatostatin being secreted and consequently higher release of gastrin and stomach acid. This, combined with the damage from ammonium, leads to ulceration of the stomach wall.

Due to the high volume or water content of fiber-rich foods, fiber displaces available calories and nutrients from the diet. Consumption of viscous fibers delays gastric emptying, which may cause an extended feeling of fullness. Satiety is also induced by increasing chewing, which limits food intake by promoting the secretion of saliva and gastric juice, resulting in an expansion of the stomach. In addition, hormone secretion is affected during fiber ingestion. Insulin response is reduced and cholecystokinin (CCK) in the small intestine is increased. Insulin regulates blood glucose levels while CCK adjusts gastric emptying, pancreatic secretion, and gall bladder contraction. There is a direct correlation between CCK and satiety after foods of different fiber contents are consumed. In general, large intakes of dietary fiber at breakfast have been associated with less food intake at lunchtime. Fiber may have the added benefit of helping consumers reduce food intake throughout the day, but results of studies examining this possibility have been conflicting.

Sources: en.wikipedia.org

Reference notes

Orthopoxviruses and some other nucleocytoplasmic large DNA viruses synthesize RNA using a virally encoded multi-subunit RNAP. They are most similar to eukaryotic RNAPs, with some subunits minified or removed. Exactly which RNAP they are most similar to is a topic of debate. Most other viruses that synthesize RNA use unrelated mechanics. Many viruses use a single-subunit DNA-dependent RNAP (ssRNAP) that is structurally and mechanistically related to the single-subunit RNAP of eukaryotic chloroplasts (RpoT) and mitochondria (POLRMT) and, more distantly, to DNA polymerases and reverse transcriptases. Perhaps the most widely studied such single-subunit RNAP is bacteriophage T7 RNA polymerase. ssRNAPs cannot proofread. B. subtilis prophage SPβ uses YonO, a homolog of the β+β′ subunits of msRNAPs to form a monomeric (both barrels on the same chain) RNAP distinct from the usual "right hand" ssRNAP. It probably diverged very long ago from the canonical five-unit msRNAP, before the time of the last universal common ancestor. Other viruses use an RNA-dependent RNAP (an RNAP that employs RNA as a template instead of DNA). This occurs in negative strand RNA viruses and dsRNA viruses, both of which exist for a portion of their life cycle as double-stranded RNA. However, some positive strand RNA viruses, such as poliovirus, also contain RNA-dependent RNAP.

== Design nanoparticle self-assembly structure == Self-assembly of nanoparticles is driven by either maximization of packing density or minimization of the contact area between particles according to hard or soft nanoparticles. Examples of hard nanoparticles are: silica, fullerenes; soft nanoparticles are often organic nanoparticles, block copolymer micelles, DNA nanoparticles. The ordered self-assembly structure of nanoparticles is called superlattice.

2024 Greater Manchester mayoral election: Labour's Andy Burnham secures a third term as Mayor of Greater Manchester with almost two-thirds of the votes cast. The SDLP announces that it will change the way it makes "civil leadership" appointments following the resignation from the party of two Derry City and Strabane District Council councillors over the appointment of Lilian Seenoi-Barr as the authority's next mayor. 5 May – With all votes counted, the results from the local elections in England are: Labour 1,158 (+186), Liberal Democrat 522 (+104), Conservative 515 (−474), Independents and others 228 (+93), Green 181 (+74), Residents' Association 48 (+11), Workers Party of Britain 4 (+4), Reform UK 2 (+2). 6 May – Argentina's president, Javier Milei, tells the BBC he accepts the Falkland Islands are currently "in the hands of the UK", but says his country will get them back through diplomatic channels. John Swinney is confirmed as Leader of the Scottish National Party after being unopposed in the leadership election, and begins his second tenure in the post. 7 May – John Swinney wins the backing of the Scottish Parliament to become Scotland's seventh First Minister, and will be sworn into office the next day. The Green Party's Siân Berry, who was re-elected in the 2024 London Assembly election, is criticised for resigning three days later to hand her seat to Zoë Garbett, who lost in the same election with 5.8% of the vote.

Incidence the rate of an occurrence of, for instance, an infection like measles or mumps or one of the types of diabetes. Infusion Set in a diabetic context, a tubing system to connect an insulin pump to the pump user, including a subcutaneous cannula, adhesive mount, quick-disconnect, and a pump cartridge connector. Ingestion Eating food, drinking water, or ingesting medicine by mouth. Injection Putting liquid into the body with a needle and syringe. Often directly into a vein, as for intravenous antibiotics in a hospital. for diabetes taking insulin, injection is usually subcutaneous (i.e. just under the skin) and not into a vein. In fact, injection of current insulins into a vein should be done only in a medical facility, and some insulin types should never be injected into a vein. Insulin a hormone produced by the beta cells in the Islet of Langerhans' beta cells. It is a very small protein and has effects all over the body, some connected with metabolism and others connected with arterial wall muscle tone, or electrolyte balances across cell membranes, etc. It is also the chief control mechanism for body metabolism. Insulin allergy This occurs when a person's body has an allergic or bad reaction to taking insulin made from non-human insulin (e.g., from pork or beef or from bacteria). the reaction can be because the insulin is not exactly the same as human insulin or because it has impurities. The allergy can be of two forms. In one, sometimes an area of skin becomes red and itchy around the place where the insulin is injected. This is called a local allergy.

Moreover, the absolute uranium concentrations indicate that there was no contamination of the earthworm species studied." Though a more comprehensive assessment is possible, a 2011 update on a cancer scare regarding Italian soldiers who had served in the Balkans found lower than expected incidence rates for all cancers, a finding "consistent with lacking evidence of an increased cancer incidence among troops of other countries deployed in the areas of Iraq, Bosnia, and Kosovo, where armour-penetrating depleted uranium shells have been used." In 2018, Serbia set up a commission of inquiry into the consequences of the use of depleted uranium during the 1999 NATO bombing of Yugoslavia in southern Serbia and its link to the rise of diseases and tumors among citizens, particularly in young children born after 1999. Zoran Radovanovic, an epidemiologist and the chairman of the Serbian Medical Association's ethics committee, denied that there had been a rise in cancer cases in areas where bombings had taken place. He continued by saying that Serbians frequently worry about a cancer epidemic that does not exist. NATO has repeatedly claimed that depleted uranium found in the ammunition used in the 1999 bombardments cannot be linked to adverse health effects.

Sources: en.wikipedia.org

Notes from published material

Shut-down separator (for overheating) Tear-away tab (for internal pressure relief) Vent (pressure relief in case of severe outgassing) Thermal interrupt (overcurrent/overcharging/environmental exposure) These features are required because the negative electrode produces heat during use, while the positive electrode may produce oxygen. However, these additional devices occupy space inside the cells, add points of failure, and may irreversibly disable the cell when activated. Further, these features increase costs compared to nickel metal hydride batteries, which require only a hydrogen/oxygen recombination device and a back-up pressure valve. Contaminants inside the cells can defeat these safety devices. Also, these features cannot be applied to all kinds of cells; prismatic high-current cells cannot be equipped with a vent or thermal interrupt. High-current cells must not produce excessive heat or oxygen, lest there be a failure, possibly violent. Instead, they must be equipped with internal thermal fuses which act before the anode and cathode reach their thermal limits. Replacing the lithium cobalt oxide positive electrode material with a lithium metal phosphate such as lithium iron phosphate (LFP) improves cycle counts, shelf life and safety, but lowers capacity. As of 2006, these safer lithium-ion batteries were mainly used in electric cars and other large-capacity battery applications, where safety is critical. In 2016, an LFP-based energy storage system was chosen to be installed in Paiyun Lodge on Mt.Jade (Yushan) (the highest lodge in Taiwan).

== Chemical properties == The substance is a constant mixture of two collagenases (AUX-I and AUX-II) with known amino acid sequences and a length of about 1000 amino acids each. It is prepared by anaerobic fermentation from a strain of C. histolyticum that has been known since 1950.

=== Ischemic stroke === Some preliminary research suggested that citicoline may reduce the rates of death and disability following an ischemic stroke. However, the largest citicoline clinical trial to date (a randomised, placebo-controlled, sequential trial of 2,298 patients with moderate-to-severe acute ischaemic stroke in Europe), found no benefit of administering citicoline on survival or recovery from stroke. A meta-analysis of seven trials reported no statistically significant benefit for long-term survival or recovery.

==== Termination of Peter Rost (2005) ==== Peter Rost was vice president in charge of the endocrinology division at Pharmacia before its acquisition by Pfizer. During that time he raised concerns internally about kickbacks and off-label marketing of Genotropin, Pharmacia's human growth hormone drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Pfizer. Pfizer kept him employed, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him, and he filed a wrongful termination suit against Pfizer. Pfizer won a summary dismissal of the case, with the court ruling that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblower activities.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network